Stockscreener 앱 받기
29.07
3.84%
1.075
시간 외 거래:
29.00
-0.075
-0.26%
전일 마감가:
$28.00
열려 있는:
$28.24
하루 거래량:
2.70M
Relative Volume:
1.28
시가총액:
$4.02B
수익:
$181.74M
순이익/손실:
$-143.97M
주가수익비율:
-20.92
EPS:
-1.39
순현금흐름:
$9.60M
1주 성능:
+31.98%
1개월 성능:
+76.53%
6개월 성능:
+67.58%
1년 성능:
+25.05%
1일 변동 폭
$28.01
$29.28
1주일 범위
$22.73
$29.34
52주 변동 폭
$9.57
$29.34
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
ARWR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
29.07 | 3.87B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Pharmaceuticals Inc. stock trendline breakdownMarket Risk Report & Daily Stock Momentum Reports - Newser
Should value investors consider Arrowhead Pharmaceuticals Inc.Share Buyback & Weekly Top Gainers Alerts - خودرو بانک
Is Arrowhead Pharmaceuticals Inc. stock risky to hold now2025 Year in Review & High Accuracy Investment Signals - خودرو بانک
News impact scoring models applied to Arrowhead Pharmaceuticals Inc.July 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
Can Arrowhead Pharmaceuticals Inc. grow without dilutionMarket Movers & Weekly Stock Performance Updates - خودرو بانک
Can Arrowhead Pharmaceuticals Inc. be recession proof2025 Historical Comparison & Safe Entry Momentum Tips - خودرو بانک
Smart tools for monitoring Arrowhead Pharmaceuticals Inc.’s price action2025 Risk Factors & Consistent Growth Equity Picks - Newser
Arrowhead Pharmaceuticals at Cantor Global Healthcare Conference - AInvest
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 09 - MarketScreener
What is Arrowhead Pharmaceuticals Inc. s 5 year growth outlookTrade Signal Summary & Free Real-Time Volume Trigger Notifications - خودرو بانک
What’s next for Arrowhead Pharmaceuticals Inc. stock priceQuarterly Trade Review & Breakout Confirmation Trade Signals - Newser
Arrowhead Pharmaceuticals Shares Drop After Sarepta Sells Stake - MSN
Arrowhead Pharmaceuticals shares rise 3.82% intraday after insider sold shares. - AInvest
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy - MSN
Identifying reversal signals in Arrowhead Pharmaceuticals Inc.2025 Fundamental Recap & Low Risk Growth Stock Ideas - Newser
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - MSN
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - Mitrade
Will earnings trigger a reversal in Arrowhead Pharmaceuticals Inc.July 2025 Retail & Verified Momentum Watchlists - Newser
Using Python tools to backtest Arrowhead Pharmaceuticals Inc. strategiesPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
How to forecast Arrowhead Pharmaceuticals Inc. trends using time seriesQuarterly Market Review & Fast Gain Stock Trading Tips - Newser
Will Arrowhead Pharmaceuticals Inc. benefit from AI trendsJuly 2025 Big Picture & Real-Time Buy Signal Notifications - خودرو بانک
Will breakout in Arrowhead Pharmaceuticals Inc. lead to full recoveryWatch List & Real-Time Market Sentiment Reports - Newser
Will Arrowhead Pharmaceuticals Inc. announce a stock splitWeekly Trend Report & AI Enhanced Trading Signals - خودرو بانک
Arrowhead Pharmaceuticals Inc (ARWR) Insider Sell: James Hamilto - GuruFocus
Analyzing recovery setups for Arrowhead Pharmaceuticals Inc. investorsJuly 2025 Macro Moves & Daily Growth Stock Investment Tips - Newser
Analyzing net buyer seller activity in Arrowhead Pharmaceuticals Inc. - Newser
Arrowhead Pharmaceuticals' Chief Medical Officer Sells 15,000 Shares at $25/Share - AInvest
Arrowhead Pharmaceuticals at Cantor Global Healthcare: Strategic Moves and Market Positioning - Investing.com
Can a trend reversal in Arrowhead Pharmaceuticals Inc. lead to recoveryPortfolio Update Summary & Verified High Yield Trade Plans - Newser
Is Arrowhead Pharmaceuticals Inc. stock entering bullish territoryWeekly Investment Recap & Entry Point Confirmation Signals - Newser
Using data models to predict Arrowhead Pharmaceuticals Inc. stock movementShare Buyback & AI Enhanced Market Trend Forecasts - Newser
Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits - Yahoo Finance
Arrowhead Pharmaceuticals at Citi’s Biopharma Conference: Strategic Insights - Investing.com
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 01 - MarketScreener
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals stock hits 52-week high at 27.35 USD - Investing.com
Tick level data insight on Arrowhead Pharmaceuticals Inc. volatilityJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser
Arrowhead and Novartis sign agreement for ARO-SNCA - BioWorld MedTech
Arrowhead Pharma stock gets Buy rating reaffirmed by H.C. Wainwright - Investing.com
Arrowhead Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Profit Report & AI Forecast for Swing Trade Picks - Newser
Arrowhead Pharmaceuticals Inc. stock momentum explained2025 Performance Recap & Technical Entry and Exit Alerts - Newser
Detecting price anomalies in Arrowhead Pharmaceuticals Inc. with AI2025 Fundamental Recap & High Accuracy Swing Trade Signals - Newser
Arrowhead Pharmaceuticals shares fall 1.40% premarket after announcing a global licensing and collaboration agreement with Novartis for ARO-SNCA. - AInvest
Using Ichimoku Cloud for Arrowhead Pharmaceuticals Inc. technicalsPortfolio Return Summary & Low Drawdown Momentum Ideas - Newser
Arrowhead Pharmaceuticals Inc. stock volume spike explainedJuly 2025 Retail & Daily Chart Pattern Signals - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Stocks To Watch: Arrowhead Pharm Sees RS Rating Jump To 89 - Investor's Business Daily
Published on: 2025-09-03 01:49:11 - Newser
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):